Bridgeway Capital Management, LLC Acelrx Pharmaceuticals Inc Transaction History

Bridgeway Capital Management, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$0.2 - $0.35 $10,000 - $17,500	-50,000 Reduced 16.49%	253,300 $53,000
Q4 2021 Feb 14, 2022	SELL	$0.49 - $1.02 $74,823 - $155,754	-152,700 Reduced 33.49%	303,300 $170,000
Q3 2021 Nov 15, 2021	SELL	$0.93 - $1.51 $49,522 - $80,407	-53,250 Reduced 10.46%	456,000 $465,000
Q2 2021 Aug 16, 2021	SELL	$1.03 - $1.7 $161,813 - $267,070	-157,100 Reduced 23.58%	509,250 $703,000
Q1 2021 May 17, 2021	BUY	$1.25 - $2.77 $462,750 - $1.03 Million	370,200 Added 125.0%	666,350 $1.13 Million
Q4 2020 Feb 16, 2021	SELL	$1.18 - $1.98 $35,400 - $59,400	-30,000 Reduced 9.2%	296,150 $367,000
Q3 2020 Nov 16, 2020	SELL	$1.01 - $1.81 $20,200 - $36,200	-20,000 Reduced 5.78%	326,150 $463,000
Q3 2018 Nov 13, 2018	BUY	$2.6 - $4.6 $260,000 - $459,999	100,000 Added 40.63%	346,150 $1.33 Million
Q2 2018 Aug 14, 2018	SELL	$2.13 - $4.2 $70,290 - $138,600	-33,000 Reduced 11.82%	246,150 $831,000
Q4 2017 Feb 14, 2018	SELL	$1.75 - $5.5 $70,000 - $220,000	-40,000 Reduced 12.53%	279,150 $565,000
Q3 2017 Nov 14, 2017	BUY	$2.9 - $4.6 $925,535 - $1.47 Million	319,150	319,150 $1.47 Million

Ticker ACRX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 7,366,600
Market Cap $8.32M
Description
AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA and DZUVEO, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company develops ZALVISO, a pre-programmed ...

Get notified when there are updates to the investment portfolio of Bridgeway Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Bridgeway Capital Management, LLC with notifications on news.